NTx Bio Launches NTxscribe FLEX for RNA Production

NTx Bio has introduced NTxscribe FLEX, a flexible benchtop continuous-flow RNA production system designed to serve the needs of process development scientists, translational researchers and RNA therapeutic developers, and support a broad range of RNA development workflows.

NTxscribe FLEX extends NTx’s NTxscribe platform, built on the same patented continuous-flow, hollow fiber bioreactor (HFBR) architecture that powers its NTxscribe CORE system. The result is a more flexible, purpose-built system that gives researchers and development teams direct control over their RNA production process, customizable to the quantities and parameters each program requires.

NTxscribe FLEX delivers an RUO system that will scale to deliver GMP material. Where NTxscribe CORE is optimized for standardized, higher-volume production, NTxscribe FLEX is purpose-built for customizability, giving researchers and process development teams the ability to dial in RNA output to what their program requires.

NTxscribe FLEX supports RNA development and clinical production needs from a compact, single-operator benchtop footprint, without requiring large-scale manufacturing infrastructure, all while remaining flexible to integrate with up and downstream solutions.

“By bringing our core technology into a more flexible, affordable and open format, we’re meeting a much broader range of customers where they are, whether that’s a process development team optimizing a new construct, a translational researcher working with complex RNA, or an emerging biotech building their RNA capabilities from the ground up,” said Joan Haab, Ph.D., CEO of NTx Bio.

NTxscribe FLEX is available for research use beginning Summer 2026. GMP availability is expected in early 2027.